‘Everyday Enhancement’: Parents and Professionals Making Decisions about Drug Treatment of Minors for Problems with Learning and Behaviour

Abstract

The use of pharmaceuticals to support learning and behaviour in children has been a controversial topic since the 1990s. Concerns have been raised about overmedicating children, thwarting their moral develop with drugs, as well as providing an unfair advantage. Everyday enhancement can be understood as the grey area between unambiguously therapeutic and unambiguously non‐therapeutic uses of medication to improve cognitive performance in children. Attention‐deficit hyperactivity (ADHD) disorder and psychostimulant medication use offer a good case study to reflect on the questions raised by everyday enhancement. Over the past years several frameworks have been developed to guide medical professionals' decision‐making. These are rooted in different ethical commitments and include a pragmatic managerial approach to reducing or preventing the harms of enhancement in children; a framework centered on the physician's fiduciary responsibility; and a framework starting from the notion of children's best interests.

Key Concepts

  • Enhancement is a controversial subject that rose to prominence from the late 1990s.
  • Evidence suggests that psychostimulant medication is being used to enhance normal performance in children and adolescents.
  • Current evidence is inconclusive about the prevalence of the practice and the efficacy of stimulants in improving normal cognitive performance.
  • Several ethical, societal and neurodevelopmental concerns have been raised about the use of psychostimulants for nonmedical purposes, although the boundaries between therapeutic and enhancing interventions may sometimes be very difficult to define.
  • Various frameworks for professional decision‐making have been formulated, which allocate different weight to a shared set of ethical and societal considerations, such as harm reduction, children's best interests and the fiduciary responsibility of physicians.

Keywords: drug; treatments; minors; decisions; behaviour; parents; ADHD; professionals; enhancement

References

Advokat C (2010) What are the cognitive effects of stimulant medications? Emphasis on adults with attention‐deficit/hyperactivity disorder (ADHD). Neuroscience & Biobehavioral Reviews 34 (8): 1256–1266.

American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Washington, DC: American Psychiatric Association.

Bagot KS and Kaminer Y (2014) Efficacy of stimulants for cognitive enhancement in non‐attention deficit hyperactivity disorder youth: a systematic review. Addiction 109 (4): 547–557.

Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL and Jacobsen SJ (2007) Long‐term school outcomes for children with attention‐deficit/hyperactivity disorder: a population‐based perspective. Journal of Developmental & Behavioral Pediatrics 28 (4): 265–273.

Bárd I and Singh I (2015) Attention Deficit Hyperactivity Disorder: Improving Performance Through Brain‐Computer Interface. Springer Netherlands pp. 741–762.

Benanti P (2010) Neuroenhancement in young people: Cultural need or medical technology?. Ajob Neuroscience 1 (1): 27–29.

Buchanan A (2011) Cognitive enhancement and education. Theory and Research in Education 9 (2): 145–162.

Castellanos FX, Lee PP, Sharp W, et al. (2002) Developmental trajectories of brain volume abnormalities in children and adolescents with attention‐deficit/hyperactivity disorder. JAMA 288 (14): 1740–1748.

Currie J, Stabile M and Jones L (2014) Do stimulant medications improve educational and behavioral outcomes for children with ADHD? Journal of Health Economics 37: 58–69.

Dalsgaard S, Mortensen PB, Frydenberg M and Thomsen PH (2014) ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood—a naturalistic long‐term follow‐up study. Addictive Behaviors 39 (1): 325–328.

Daniels N (2000) Normal functioning and the treatment‐enhancement distinction. Cambridge Quarterly of Healthcare Ethics 9: 309–322.

de Melo‐Martín I (2010) Not all means are created equal and some other problems. AJOB Neuroscience 1 (1): 17–18.

Diller LH (1996) The run on Ritalin: attention deficit disorder and stimulant treatment in the 1990s. Hastings Center Report 26 (2): 12–18.

Elliott C (1998) The tyranny of happiness: ethics and cosmetic psychopharmacology. In: Parens E (ed.) Enhancing Human Traits: Ethical and Social Implications, pp. 135–150. Washington, DC: Georgetown University Press.

Farah MJ (2015) The unknowns of cognitive enhancement. Science 350 (6259): 379–380.

Franke AG, Bonertz C, Christmann M, et al. (2011) Non‐medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 44 (2): 60.

Freedman C (1998) Aspirin for the mind? Some ethical worries about psychopharmacology. In: Parens E (ed.) Enhancing Human Traits: Ethical and Social Implications, pp. 135–150. Washington, DC: Georgetown University Press.

Fukuyama F (2002) Our Posthuman Future. New York, NY: Picador Press.

Garfield CF, Dorsey R, Zhu S, et al. (2012) Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000–2010. Academic Pediatrics 12: 110–116.

Gaucher N, Payot A and Racine E (2013) Cognitive enhancement in children and adolescents: is it in their best interests? Acta Paediatrica 102 (12): 1118–1124.

Graf WD, Nagel SK, Epstein LG, et al. (2013) Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications. Neurology 80 (13): 1251–1260.

Gualtieri CT and Johnson LG (2005) ADHD: is objective diagnosis possible? Psychiatry (Edgmont) 2 (11): 44–53.

Hall WD and Lucke JC (2010) The enhancement use of neuropharmaceuticals: more scepticism and caution needed. Addiction 105 (12): 2041–2043.

Harris J (2007) Enhancing evolution: The ethical case for making people better. Princeton: Princeton University Press.

Ilieva I, Boland J and Farah MJ (2013) Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology 64: 496–505.

Kass L (2004) Life, Liberty and the Defense of Dignity. San Francisco, CA: Encounter Books.

Kazerooni H (2007) Human augmentation and exoskeleton systems in Berkeley. International Journal of Humanoid Robotics 4 (03): 575–605.

King MD, Jennings J and Fletcher JM (2014) Medical adaptation to academic pressure schooling, stimulant use, and socioeconomic status. American Sociological Review 79 (6): 1039–1066.

Kramer PD (1997) Listening to Prozac: The Landmark Book about Antidepressants and the Remaking of the Self. New York, NY: Viking Penguin.

Krause B and Kadosh RC (2013) Can transcranial electrical stimulation improve learning difficulties in atypical brain development? A future possibility for cognitive training. Developmental Cognitive Neuroscience 6: 176–194.

Liakoni E, Schaub MP, Maier LJ, Glauser G‐V and Liechti ME (2015) The use of prescription drugs, recreational drugs, and “soft enhancers” for cognitive enhancement among Swiss Secondary School Students. PLoS One 10 (10): e0141289. DOI: 10.1371/journal.pone.0141289.

Maier LJ, Liechti ME, Herzig F and Schaub MP (2013) To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss University Students. PLoS One 8 (11): e77967. DOI: 10.1371/journal.pone.0077967.

Marcus DK and Barry TD (2011) Does attention‐deficit/hyperactivity disorder have a dimensional latent structure? A taxometric analysis. Journal of Abnormal Psychology 120 (2): 427–442. DOI: 10.1037/a0021405.

Martin J, Hamshere ML, Stergiakouli E, O'Donovan MC and Thapar A (2014) Genetic risk for attention‐deficit/hyperactivity disorder contributes to neurodevelopmental traits in the general population. Biological Psychiatry 76 (8): 664–671.

Molina BSG, Hinshaw SP, Swanson JM, et al. (2009) The MTA at 8 years: prospective follow‐up of children treated for combined type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry 48 (5): 484–500. DOI: 10.1097/CHI.0b013e31819c23d0.

Montoya A, Colom F and Ferrin M (2011) Is psychoeducation for parents and teachers of children and adolescents with ADHD efficacious? A systematic literature review. European Psychiatry 26 (3): 166–175.

Myers RL (2007) The 100 Most Important Chemical Compounds: A Reference Guide. Westport, CT: ABC‐CLIO.

Parens E (1998) Enhancing Human Traits: Ethical and Social Implications. Washington, DC: Georgetown University Press.

Parens E (2014) Shaping Our Selves: On Technology, Flourishing and a Habit of Thinking. New york: Oxford University Press.

Polanczyk G, de Lima MS, Horta BL, Biederman J and Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry 164: 942–948.

Polanczyk G and Jensen P (2008) Epidemiological considerations in attention deficit hyperactivity disorder: a review and update. Child and Adolescent Psychiatric Clinics of North America 17: 245–260.

President's Council on Bioethics (US) and Kass L (2003) Beyond Therapy: Biotechnology and the Pursuit of Happiness. Washington, DC: Harper Perennial.

Ragan CI, Bard I and Singh I (2013) What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 64: 588–595.

Repantis D, Schlattmann P, Laisney O and Heuser I (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacological Research 62 (3): 187–206.

Rusconi E and Mitchener‐Nissen T (2014) The role of expectations, hype and ethics in neuroimaging and neuromodulation futures. Frontiers in Systems Neuroscience 8: 214.

Savulescu J, Sandberg A and Kahane G (2011) Well‐being and enhancement. In: Savulescu J, ter Meulen R and Kahane G (eds) Enhancing Human Capacities, pp. 243–260. Chichester, West Sussex, U.K. ; Malden, MA: Wiley‐Blackwell.

Scheffler RM, Brown TT, Fulton BD, et al. (2009) Positive association between attention‐deficit/hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics 123 (5): 1273–1279.

Singh I (2008) Beyond polemics: science and ethics of ADHD. Nature Reviews Neuroscience 9 (12): 957–964.

Singh I and Kelleher KJ (2010) Neuroenhancement in young people: proposal for research, policy, and clinical management. AJOB Neuroscience 1 (1): 3–16.

Smith MF and Farah MJ (2011) Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin 137 (5): 717–741.

Singh I, Bard I and Jackson J (2014) Robust resilience and substantial interest: a survey of pharmacological cognitive enhancement among university students in the UK and Ireland. PLoS One 9 (10): e105969.

Singh I and Wessely S (2015) Childhood: a suitable case for treatment? Lancet Psychiatry 2 (7): 661–666.

Sonuga‐Barke EJ, Brandeis D, Cortese S, et al. (2014) Nonpharmacological interventions for ADHD: systematic review and meta‐analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry 170 (3): 275–289.

Swanson JM, Wigal T and Lakes K (2009) DSM‐V and the future diagnosis of attention deficit/hyperactivity disorder. Current Psychiatry Reports 11 (5): 399–406.

Swanson JM, Wigal T and Volkow ND (2011) Contrast of medical and nonmedical use of stimulant drugs: basis for the distinction, and risk of addiction: comment on Smith and Farah. Psychological Bulletin 137 (5): 742–748.

Visser SN, Danielson ML, Bitsko RH, et al. (2014) Trends in the parent‐report of health care provider‐diagnosed and medicated attention‐deficit/hyperactivity disorder: United States, 2003–2011. Journal of the American Academy of Child and Adolescent Psychiatry 53 (1): 34–46.

Vrecko S (2013) Just how cognitive is “cognitive enhancement”? On the significance of emotions in university students' experiences with study drugs. AJOB Neuroscience 4 (1): 4–12.

Wilens TE, Faraone SV, Biederman J and Gunawardene S (2003) Does stimulant therapy of attention‐deficit/hyperactivity disorder beget later substance abuse? A meta‐analytic review of the literature. Pediatrics 111 (1): 179–185.

Zoëga H, Rothman KJ, Huybrechts KF, et al. (2012) A population‐based study of stimulant drug treatment of ADHD and academic progress in children. Pediatrics 130 (1): e53–e62.

Zohny H (2015) The myth of cognitive enhancement drugs. Neuroethics 8 (3): 257–269.

Further Reading

Berger I, Dor T, Nevo Y and Goldzweig G (2008) Attitudes toward attention‐deficit hyperactivity disorder (ADHD) treatment: parents' and children's perspectives. Journal of Child Neurology 23 (9): 1036–1042, first published on May 16, 2008. DOI: 10.1177/0883073808317726.

Clausen J and Levy N (2015) Springer Handbook of Neuroethics. Dordrecht: Springer Science & Business Media.

Hildt E and Franke AG (eds) (2013) Cognitive Enhancement: An Interdisciplinary Perspective, vol. 1. Dordrecht: Springer Science & Business Media.

Pugh J (2014) Enhancing autonomy by reducing impulsivity: the case of ADHD. Neuroethics 7 (3): 373–375.

Singh I (2012) Not robots: children's perspectives on authenticity, moral agency and stimulant drug treatments. Journal of Medical Ethics. 2013 Jun; 39 (6): 359–366. DOI: 10.1136/medethics‐2011‐100224.

Singh I, Sinnott‐Armstrong WP and Savulecu J (eds) (2013) Bioprediction, Biomarkers, and Bad Behavior: Scientific, Legal, and Ethical Challenges. New york, NY: Oxford University Press.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Bard, Imre, Singh, Ilina, and Eduard, Peter(Jan 2017) ‘Everyday Enhancement’: Parents and Professionals Making Decisions about Drug Treatment of Minors for Problems with Learning and Behaviour. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0026494]